ENLV Enlivex Therapeutics Ltd: שווי החברה בספרים

The share price history of Enlivex Therapeutics (ENLV) reflects the dynamics of a company developing cell therapy to combat sepsis, with the indicator standing at 3.88. The production base relies on an Israeli high-tech complex featuring autonomous power supply and redundant filters. To accelerate drug registration, the business is implementing software robots for data processing and automated molecular screening stations.

The lack of operating cash flow at Enlivex Therapeutics (ENLV) leaves the company dependent on external financing for its clinical developments. The trend in the firm's book value of equity reflects the remaining net assets minus liabilities, allowing investors to assess the real value of the business and avoid overpaying for unjustified market expectations.